

Masquerade of marauders: Sweet Syndrome, zoster, and hepatitis C

Madeline J. Hooper, BA¹; Martin C. DelaTorre, DO²; Monica B. Mistry, DO²

¹Morsani College of Medicine, University of South Florida, Tampa, FL ²Department of Internal Medicine, Lehigh Valley Health Network, Allentown, PA

Background

- Sweet syndrome (SS) is a febrile neutrophilic dermatosis often associated with infection, malignancy, and medications.¹⁻⁷
- SS is defined by the acute eruption of painful cutaneous lesions with histopathological evidence of dense neutrophilic infiltration. It can affect mucous membranes, the central nervous system and viscera.
- A minor diagnostic criterion of SS is excellent response to IV high-dose corticosteroids.

Objective

To describe a corticosteroid-refractory case of bullous Sweet Syndrome complicated by varicella zoster (VZV) and untreated hepatitis C (HCV).

Case Presentation

HPI

- 75-year-old man with end stage renal disease and untreated HCV presents with a hemorrhagic, necrotic rash on his face with oral involvement and tense bullae on his bilateral extremities (Figures 1 and 2).



Figures 1 & 2: Facial rash (1) and bullae on bilateral arms (2), Day 1.

- Five days prior, he had received IV cefepime, levofloxacin and vancomycin, and undergone contrast CT for febrile encephalopathy at an outside hospital.

Allergies

- Piperacillin-tazobactam (anaphylaxis), ciprofloxacin (rash), metronidazole (rash)

Hospital Course

Day 1

- Afebrile, hemodynamically stable
- Rash covers 10% body surface area (BSA)
- Negative Nikolsky's sign
- **Start** IV methylprednisolone 50mg BID

Day 2

- Burn and Dermatology favor diagnosis of bullous SS
- Punch biopsy of the scalp: diffuse dermal neutrophilic infiltrate consistent with SS
- **Add** hydrocortisone 2.5% and triamcinolone 0.1% ointments

Day 3

- Rash progresses to 30% BSA; larger, more numerous bullae in mouth (Figure 3) and on extremities
- Leukocyte count 10,800, 94% neutrophils
- Serology: HbsAb+, HcAb+, HCV viral load 38,400 IU/L
- Direct fluorescent antibody on leg lesion sample VZV+
- Blood cultures, HIV 1/2 Ag/Ab, HSV probe negative
- **Start** IV acyclovir 5mg/kg QD



Figure 3. Oral bullae, Day 3.

Day 8

- Widespread skin necrosis in areas of rash (Figure 4)
- Autoimmune panel: high levels of ANA, anti-dsDNA and anti-Ro/SSA antibodies

Day 10

- Patient died from medical complications



Figure 4: Facial rash, Day 8.

Discussion

Suspected trigger(s) of this patient's bullous SS

- Drug-induced
 - Contrast dye
 - Hydralazine
 - Antibiotics
- Occult hematologic malignancy^{4,8}
 - Age > 65 years
 - Anemia (hemoglobin 9.4, Day 1)
 - Thrombocytopenia (platelets 90, Day 1)
 - Absence of arthralgias
- Respiratory infection, sacral wound infection

Literature review

- Only one case of dermatomal bullous SS triggered by herpes simplex virus and three cases of SS in the setting of HCV have been published.⁹⁻¹²
- No data clarify if the relationship between this patient's HCV, autoimmunity, and SS was causal or benign.

Conclusions

- Unique to our case is its myriad possible etiologies.
- Because SS may not regress without treatment of the underlying cause, elucidating the precipitating event remains important on a case-by-case basis. This element of SS management requires further study.

References

1. Cohen, P.R., Sweet's syndrome--a comprehensive review of an acute febrile neutrophilic dermatosis. *Orphanet J Rare Dis*, 2007. 2: p. 34.
2. Juanola, X., et al., Hydralazine induced lupus and Sweet's syndrome. *J Rheumatol*, 1991. 18(6): p. 948.
3. Kato, T., et al., Case of Sweet's syndrome with extensive necrosis and ulcers accompanied by myelodysplastic syndrome. *J Nippon Med Sch*, 2008 75(3): p. 162-5.
4. Marcovat, J., et al., Sweet syndrome: long-term follow-up of 138 patients. *Clin Exp Dermatol*, 2016. 41(7): p. 741-6.
5. Raza, S., et al., Insight into Sweet's syndrome and associated-malignancy: a review of the current literature. *Int J Oncol*, 2013. 42(5): p. 1516-22.
6. Rochet, N.M., et al., Sweet syndrome: clinical presentation, associations, and response to treatment in 77 patients. *J Am Acad Dermatol*, 2013. 69(4): p. 557-64.
7. Walker, D.C. and P.R. Cohen, Trimethoprim-sulfamethoxazole-associated acute febrile neutrophilic dermatosis: case report and review of drug-induced Sweet's syndrome. *J Am Acad Dermatol*, 1996. 34(5 Pt 2): p. 918-23.
8. Nelson, C.A., et al., Sweet syndrome in patients with and without malignancy: A retrospective analysis of 83 patients from a tertiary academic referral center. *J Am Acad Dermatol*, 2018. 78(2): p. 303-309.e4.
9. Endo, Y., et al., Bullous Variant of Sweet's Syndrome after Herpes Zoster Virus Infection. *Case Rep Dermatol*, 2011. 3(3): p. 259-62.
10. Baz, K., et al., Neutrophilic dermatosis of the hands (localized Sweet's syndrome) in association with chronic hepatitis C and sarcoidosis. *Clin Exp Dermatol*, 2003. 28(4): p. 377-9.
11. Guo, D. and L.M. Parsons, Sweet syndrome in a patient with chronic hepatitis C. *J Cutan Med Surg*, 2014. 18(6): p. 436-8.
12. Deasy, A.M., et al., Sweet's syndrome in a patient with haemophilia, HIV and hepatitis C infection. *Int J STD AIDS*, 2012. 23(6): p. e11-3.